Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2021 | Obituary

José Baselga M.D., Ph.D. (1959–2021) leading cancer researcher and oncologist

Authors: Moshe Elkabets, Giovanni Blandino

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Excerpt

On March 21st, 2021, one of the most remarkable leaders in oncology Dr. José Baselga – friend, colleague and mentor – passed away before his time. The entire cancer research and oncology community was shocked by the premature death of José, who for three decades led the therapeutic revolution towards personalized/precision medicine using targeted therapies. José’s ability to envisage treatment in the years ahead led him to become one of the best-known leaders in drug development in medical oncology. …

Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-Diamminedichloroplatinum on well established A431 cell Xenografts. Cancer Res. 1993;53:4637-42.

Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst. 1993;85:1327–33 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/8340945/.CrossRef

Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Aman M, Hoda S, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung1. 1993.

Baselga J, Norton L, Albanell J, Kim Y-M, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptinâ¢) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer Xenografts. Cancer Res. 1998;58(13):2825-31.

Baselga J, Seidman AD, Peter Rosen P, Norton L. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology. 1997:43–8 [cited 2021 Apr 18]. Available from: https://europepmc.org/article/med/9110342.

Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000;18:904–14 [cited 2021 Apr 18]Available from: https://pubmed.ncbi.nlm.nih.gov/10673534/.CrossRef

Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16:2659–71 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/9704716/.CrossRef

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737–44 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/8622019/.CrossRef

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab Emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91 [cited 2021 Apr 18]Available from: https://pubmed.ncbi.nlm.nih.gov/23020162/.CrossRef

10.

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus Cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78 [cited 2021 Apr 18]. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa053422.CrossRef

11.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/16236737/.CrossRef

12.

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/11248153/.CrossRef

13.

Eichhorn PJA, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 2008;68:9221–30 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/19010894/.CrossRef

14.

O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500–8 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/16452206/.CrossRef

15.

García-García C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, et al. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res. 2012;18:2603–12 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/22407832/.CrossRef

16.

Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012;2:1036–47 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/22915752/.CrossRef

17.

Serra V, Scaltriti M, Prudkin L, Eichhorn PJA, Ibrahim YH, Chandarlapaty S, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011;30:2547–57 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/21278786/.CrossRef

18.

Serra V, Markman B, Scaltriti M, Eichhorn PJA, Valero V, Guzman M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008;68:8022–30 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/18829560/.CrossRef

19.

Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, et al. MTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med. 2013;5 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/23903756/.

20.

Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3) Kα inhibitor. Nature. 2015;518:240–4 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/25409150/.CrossRef

21.

Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, et al. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal. 2014;7 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/24667376/.

22.

Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med. 2015;7 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/25877889/.

23.

Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, et al. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science (80- ). 2017;355:1324–30 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/28336670/.CrossRef

24.

Arruabarrena-Aristorena A, Maag JLV, Kittane S, Cai Y, Karthaus WR, Ladewig E, et al. FOXA1 mutations reveal distinct chromatin profiles and influence therapeutic response in breast cancer. Cancer Cell. 2020;38:534–550.e9 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/32888433/.CrossRef

25.

Castel P, Ellis H, Bago R, Toska E, Razavi P, Carmona FJ, et al. PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3Kα inhibition. Cancer Cell. 2016;30:229–42 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/27451907/.CrossRef

26.

Toska E, Castel P, Chhangawala S, Arruabarrena-Aristorena A, Chan C, Hristidis VC, et al. PI3K inhibition activates SGK1 via a feedback loop to promote chromatin-based regulation of ER-dependent gene expression. Cell Rep. 2019;27:294–306.e5 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/30943409/.CrossRef

27.

Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, et al. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR Axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell. 2015;27:533–46 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/25873175/.CrossRef

28.

Zumsteg ZS, Morse N, Krigsfeld G, Gupta G, Higginson DS, Lee NY, et al. Taselisib (GDC-0032), a potent β-sparing small molecule inhibitor of PI3K, radiosensitizes head and neck squamous carcinomas containing activating PIK3CA alterations. Clin Cancer Res. 2016;22:2009–19 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/26589432/.CrossRef

29.

Castel P, Carmona FJ, Grego-Bessa J, Berger MF, Viale A, Anderson KV, et al. Somatic PIK3CA mutations as a driver of sporadic venous malformations. Sci Transl Med. 2016;8 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/27030594/.

30.

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122–31 [cited 2021 Apr 22]. Available from: https://pubmed.ncbi.nlm.nih.gov/28581356/.CrossRef

31.

Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay J-Y, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726–36 [cited 2021 Apr 22]. Available from: https://pubmed.ncbi.nlm.nih.gov/26287849/.CrossRef

32.

Raje N, Chau I, Hyman DM, Ribrag V, Blay J-Y, Tabernero J, et al. Vemurafenib in patients with relapsed refractory multiple myeloma harboring BRAF V600 mutations: a cohort of the histology-independent VE-BASKET study. 2018;2:1–9 [cited 2021 Apr 22]. Available from: https://pubmed.ncbi.nlm.nih.gov/32913989/.

33.

Shukla N, Roberts SS, Baki MO, Mushtaq Q, Goss PE, Park BH, et al. Successful targeted therapy of refractory pediatric ETV6-NTRK3 fusion-positive secretory breast carcinoma. JCO Precis Oncol. 2017;2017:1–8 [cited 2021 Apr 22]. Available from: https://pubmed.ncbi.nlm.nih.gov/29623306/.

34.

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34:427–438.e6 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/30205045/.CrossRef

35.

Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, et al. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Ka inhibitors. Science (80- ). 2019;366:714–23 [cited 2021 Apr 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/31699932/.CrossRef

Title: José Baselga M.D., Ph.D. (1959–2021) leading cancer researcher and oncologist
Authors: Moshe Elkabets
Giovanni Blandino
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-01966-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

Correction to: Genistein inhibits stemness of SKOV3 cells induced by macrophages co-cultured with ovarian cancer stem-like cells through IL-8/STAT3 axis

Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ

Inhibition of retinoic acid receptor α phosphorylation represses the progression of triple-negative breast cancer via transactivating miR-3074-5p to target DHRS3

The Anterior GRadient (AGR) family proteins in epithelial ovarian cancer

Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer

Correction to: Long non-coding RNA SLC2A1-AS1 induced by GLI3 promotes aerobic glycolysis and progression in esophageal squamous cell carcinoma by sponging miR-378a-3p to enhance Glut1 expression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer